Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2554-2558
© 1997 American Heart Association, Inc.
Articles |
Elevated Fasting Total Plasma Homocysteine Levels and Cardiovascular Disease Outcomes in Maintenance Dialysis Patients
A Prospective Study
From the Vitamin Bioavailability Laboratory (A.G.B., M.R.N., P.F.J., J.S., I.H.R.), Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts New England Medical Center, Boston, Mass; the Division of Renal Diseases (D.S., L.D.), Rhode Island Hospital, Providence, RI; and the Department of Nutrition (P.V.), Agricultural University, Wageningen, Netherlands.
Abstract There is an excess prevalence of
hyperhomocysteinemia in dialysis-dependent end-stage renal disease
(ESRD) patients. Cross-sectional studies of the relationship between
elevated total homocysteine (tHcy) levels and prevalent
cardiovascular disease (CVD) in this patient population
suffer from severe methodologic limitations. No prospective
investigations examining the association between tHcy levels and the
subsequent development of arteriosclerotic CVD
outcomes among maintenance dialysis patients have been
reported. To assess whether elevated plasma tHcy is an independent risk
factor for incident CVD in dialysis-dependent ESRD patients, we studied
73 maintenance peritoneal dialysis or hemodialysis patients who
received a baseline examination between March and December 1994, with
follow-up through April 1, 1996. We determined the incidence of
nonfatal and fatal CVD events, which included all validated
coronary heart disease, cerebrovascular disease, and abdominal
aortic/lower-extremity arterial disease outcomes. After a
median follow-up of 17.0 months, 16 individuals experienced at least
one arteriosclerotic CVD event. Cox
proportional-hazards regression analyses, unadjusted and
individually adjusted for creatinine, albumin, and
total cholesterol levels, total/HDL cholesterol
ratio, dialysis adequacy/residual renal function, baseline CVD, and the
established CVD risk factors (ie, age, sex, smoking, hypertension,
diabetes/glucose intolerance, and dyslipidemia) revealed
that tHcy levels in the upper quartile (
27.0 µmol/L) versus
the lower three quartiles (<27.0 µmol/L) were associated with
relative risk estimates (hazards ratios, with 95% confidence intervals
for the occurrence of (pooled) nonfatal and fatal CVD ranging from 3.0
to 4.4; 95% confidence intervals (1.1-8.1) to (1.6-12.2). We conclude
that the markedly elevated fasting tHcy levels found in
dialysis-dependent ESRD patients may contribute independently to their
excess incidence of fatal and nonfatal CVD outcomes.
Key Words: hyperhomocysteinemia • end-stage renal disease • arteriosclerosis • longitudinal study
This article has been cited by other articles:
 |
|
 |
|
  I. Baragetti, S. Raselli, A. Stucchi, V. Terraneo, S. Furiani, L. Buzzi, K. Garlaschelli, E. Alberghini, A. L. Catapano, and G. Buccianti Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3292 - 3297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Jamison, P. Hartigan, J. S. Kaufman, D. S. Goldfarb, S. R. Warren, P. D. Guarino, J. M. Gaziano, and For the Veterans Affairs Site Investigators Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A Randomized Controlled Trial JAMA, September 12, 2007; 298(10): 1163 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Undas, M. Kolarz, G. Kopec, R. Glowacki, E. Placzkiewicz-Jankowska, and W. Tracz Autoantibodies against N-homocysteinylated proteins in patients on long-term haemodialysis Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1685 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wattanakit, A. R. Folsom, E. Selvin, J. Coresh, A. T. Hirsch, and B. D. Weatherley Kidney Function and Risk of Peripheral Arterial Disease: Results from the Atherosclerosis Risk in Communities (ARIC) Study J. Am. Soc. Nephrol., February 1, 2007; 18(2): 629 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Suliman, P. Stenvinkel, A. R. Qureshi, K. Kalantar-Zadeh, P. Barany, O. Heimburger, E. F. Vonesh, and B. Lindholm The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation Nephrol. Dial. Transplant., January 1, 2007; 22(1): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Boger, M. Stubanus, T. Haak, A. K. Gotz, J. Christ, U. Hoffmann, G. A. J. Riegger, B. K. Kramer, and for the GENDIAN Study Group Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy Nephrol. Dial. Transplant., January 1, 2007; 22(1): 154 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Menon, M. J. Sarnak, T. Greene, X. Wang, A. A. Pereira, G. J. Beck, J. W. Kusek, J. Selhub, A. J. Collins, A. S. Levey, et al. Relationship Between Homocysteine and Mortality in Chronic Kidney Disease Circulation, March 28, 2006; 113(12): 1572 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Friedman, L. G. Hunsicker, J. Selhub, A. G. Bostom, and for the Collaborative Study Group Total Plasma Homocysteine and Arteriosclerotic Outcomes in Type 2 Diabetes with Nephropathy J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3397 - 3402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D Kopple The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure Am. J. Clinical Nutrition, June 1, 2005; 81(6): 1257 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vanholder, Z. Massy, A. Argiles, G. Spasovski, F. Verbeke, N. Lameire, and for the European Uremic Toxin Work Group (EUTox) Chronic kidney disease as cause of cardiovascular morbidity and mortality Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1048 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Suliman, P. Barany, K. Kalantar-Zadeh, B. Lindholm, and P. Stenvinkel Homocysteine in uraemia--a puzzling and conflicting story Nephrol. Dial. Transplant., January 1, 2005; 20(1): 16 - 21. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Obeid, M. K. Kuhlmann, H. Kohler, and W. Herrmann Response of Homocysteine, Cystathionine, and Methylmalonic Acid to Vitamin Treatment in Dialysis Patients Clin. Chem., January 1, 2005; 51(1): 196 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Winkelmayer, R. Kramar, G. C. Curhan, A. Chandraker, G. Endler, M. Fodinger, W. H. Horl, and G. Sunder-Plassmann Fasting Plasma Total Homocysteine Levels and Mortality and Allograft Loss in Kidney Transplant Recipients: A Prospective Study J. Am. Soc. Nephrol., January 1, 2005; 16(1): 255 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L Jamison, P. Hartigan, J M. Gaziano, S. P Fortmann, D. S Goldfarb, J. A Haroldson, J. Kaufman, P. Lavori, K. S McCully, and K. Robinson Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study Clinical Trials, October 1, 2004; 1(5): 451 - 460. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Rahman, C. D. Brown, J. Coresh, B. R. Davis, J. H. Eckfeldt, N. Kopyt, A. S. Levey, C. Nwachuku, S. Pressel, E. Reisin, et al. The Prevalence of Reduced Glomerular Filtration Rate in Older Hypertensive Patients and Its Association With Cardiovascular Disease: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Arch Intern Med, May 10, 2004; 164(9): 969 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Wrone, J. M. Hornberger, J. L. Zehnder, L. M. McCann, N. S. Coplon, and S. P. Fortmann Randomized Trial of Folic Acid for Prevention of Cardiovascular Events in End-Stage Renal Disease J. Am. Soc. Nephrol., February 1, 2004; 15(2): 420 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kalantar-Zadeh, G. Block, M. H. Humphreys, C. J. McAllister, and J. D. Kopple A Low, Rather than a High, Total Plasma Homocysteine Is an Indicator of Poor Outcome in Hemodialysis Patients J. Am. Soc. Nephrol., February 1, 2004; 15(2): 442 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Refsum, A. D. Smith, P. M. Ueland, E. Nexo, R. Clarke, J. McPartlin, C. Johnston, F. Engbaek, J. Schneede, C. McPartlin, et al. Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion Clin. Chem., January 1, 2004; 50(1): 3 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. D. Vriese, M. Langlois, D. Bernard, I. Geerolf, L. Stevens, J. R. Boelaert, M. Schurgers, and E. Matthys Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2596 - 2600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension, November 1, 2003; 42(5): 1050 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation, October 28, 2003; 108(17): 2154 - 2169. [Full Text] [PDF]
|
|
|
|
|
|
R. Meleady, P. M Ueland, H. Blom, A. S Whitehead, H. Refsum, L. E Daly, S. E. Vollset, C. Donohue, B. Giesendorf, I. M Graham, et al. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project Am. J. Clinical Nutrition, January 1, 2003; 77(1): 63 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bayes, M. C. Pastor, J. Bonal, J. Junca, J. M. Hernandez, N. Riutort, A. Foraster, and R. Romero Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients Nephrol. Dial. Transplant., January 1, 2003; 18(1): 106 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. De Bree, W. M. M. Verschuren, D. Kromhout, L. A. J. Kluijtmans, and H. J. Blom Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease Pharmacol. Rev., December 1, 2002; 54(4): 599 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. De Bree, W. M. Verschuren, D. Kromhout, L. I Mennen, H. J Blom, E. S Ford, S J. Smith, D. F Stroup, K. K Steinberg, P. W Mueller, et al. Homocysteine and coronary heart disease: the importance of a distinction between low and high risk subjects Int. J. Epidemiol., December 1, 2002; 31(6): 1268 - 1272. [Full Text] [PDF]
|
|
|
|
|
|
E. S Ford, S J. Smith, D. F Stroup, K. K Steinberg, P. W Mueller, and S. B Thacker Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies Int. J. Epidemiol., February 1, 2002; 31(1): 59 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kronenberg, E. Kuen, E. Ritz, P. Konig, G. Kraatz, K. Lhotta, J. F. E. Mann, G. A. Muller, U. Neyer, W. Riegel, et al. Apolipoprotein A-IV Serum Concentrations Are Elevated in Patients with Mild and Moderate Renal Failure J. Am. Soc. Nephrol., February 1, 2002; 13(2): 461 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bayes, M. C. Pastor, J. Bonal, J. Junca, and R. Romero Homocysteine and lipid peroxidation in haemodialysis: role of folinic acid and vitamin E Nephrol. Dial. Transplant., November 1, 2001; 16(11): 2172 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Davies, E. G. Wilmshurst, A. McElduff, J. Gunton, P. Clifton-Bligh, and G. R. Fulcher The Relationship Among Homocysteine, Creatinine Clearance, and Albuminuria in Patients With Type 2 Diabetes Diabetes Care, October 1, 2001; 24(10): 1805 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tice, E. Ross, P. G. Coxson, I. Rosenberg, M. C. Weinstein, M. G. M. Hunink, P. A. Goldman, L. Williams, and L. Goldman Cost-effectiveness of Vitamin Therapy to Lower Plasma Homocysteine Levels for the Prevention of Coronary Heart Disease: Effect of Grain Fortification and Beyond JAMA, August 22, 2001; 286(8): 936 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Vollset, H. Refsum, A. Tverdal, O. Nygard, J. E. Nordrehaug, G. S Tell, and P. M. Ueland Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study Am. J. Clinical Nutrition, July 1, 2001; 74(1): 130 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. El-Khairy, P. M. Ueland, H. Refsum, I. M. Graham, and S. E. Vollset Plasma Total Cysteine as a Risk Factor for Vascular Disease : The European Concerted Action Project Circulation, May 29, 2001; 103(21): 2544 - 2549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Suliman, J. C. D. Filho, P. Barany, B. Anderstam, B. Lindholm, and J. Bergstrom Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients Nephrol. Dial. Transplant., January 1, 2001; 16(1): 102 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. M. Smits, J. van der Linden, P. J. Blankestijn, and T. J. Rabelink Coagulation and haemodialysis access thrombosis Nephrol. Dial. Transplant., November 1, 2000; 15(11): 1755 - 1760. [Full Text] [PDF]
|
|
|
|
|
|
S. T. W. Morris, J. J. V. McMurray, R. S. C. Rodger, and A. G. Jardine Impaired endothelium-dependent vasodilatation in uraemia Nephrol. Dial. Transplant., August 1, 2000; 15(8): 1194 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. House, G. A. Wells, J. G. Donnelly, S. P. Nadler, and P. C. Hebert Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids Nephrol. Dial. Transplant., July 1, 2000; 15(7): 1029 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. SUNDER-PLASSMANN, M. FÖDINGER, H. BUCHMAYER, M. PAPAGIANNOPOULOS, J. WOJCIK, J. KLETZMAYR, B. ENZENBERGER, O. JANATA, W. C. WINKELMAYER, G. PAUL, et al. Effect of High Dose Folic Acid Therapy on Hyperhomocysteinemia in Hemodialysis Patients: Results of the Vienna Multicenter Study J. Am. Soc. Nephrol., June 1, 2000; 11(6): 1106 - 1116. [Abstract] [Full Text]
|
|
|
|
|
|
A. G. BOSTOM Homocysteine: "Expensive Creatinine" or Important,Modifiable Risk Factor for Arteriosclerotic Outcomes in Renal TransplantRecipients? J. Am. Soc. Nephrol., January 1, 2000; 11(1): 149 - 151. [Full Text]
|
|
|
|
|
|
L. El-Khairy, P. M Ueland, O. Nygard, H. Refsum, and S. E Vollset Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: the Hordaland Homocysteine Study Am. J. Clinical Nutrition, December 1, 1999; 70(6): 1016 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jungers, D. Joly, Z. Massy, P. Chauveau, A.-T. Nguyen, J. Aupetit, and B. Chadefaux Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2903 - 2906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Bostom and J. Selhub Homocysteine and Arteriosclerosis : Subclinical and Clinical Disease Associations Circulation, May 11, 1999; 99(18): 2361 - 2363. [Full Text] [PDF]
|
|
|
|
|
|
D. SHEMIN, K. L. LAPANE, L. BAUSSERMAN, E. KANAAN, S. KAHN, L. DWORKIN, and A. G. BOSTOM Plasma Total Homocysteine and Hemodialysis Access Thrombosis: AProspective Study J. Am. Soc. Nephrol., May 1, 1999; 10(5): 1095 - 1099. [Abstract] [Full Text]
|
|
|
|
|
|
A. G. BOSTOM and B. F. CULLETON Hyperhomocysteinemia in Chronic Renal Disease J. Am. Soc. Nephrol., April 1, 1999; 10(4): 891 - 900. [Full Text]
|
|
|
|
|
|
M. R. Malinow, A. G. Bostom, and R. M. Krauss Homocyst(e)ine, Diet, and Cardiovascular Diseases : A Statement for Healthcare Professionals From the Nutrition Committee, American Heart Association Circulation, January 12, 1999; 99(1): 178 - 182. [Full Text] [PDF]
|
|